Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG
NCT ID: NCT03208972
Last Updated: 2021-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
107 participants
INTERVENTIONAL
2014-10-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
NCT03177538
D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists
NCT01633580
Corifollitropin Alfa and Embryo Morphokinetics
NCT04142190
Use of Corifolitropin Alfa in Oocyte Donors
NCT02213627
Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
NCT06879002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
low dose hCG (Pregnyl)
Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
low dose hCG
Corifollitropin Alfa
Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.
\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG
hp-FSH (Menopur)
Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
hp-FSH
Corifollitropin Alfa
Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.
\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low dose hCG
hp-FSH
Corifollitropin Alfa
Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.
\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cycle 1, 2, 3, 4
Exclusion Criteria
* Endocrinological diseases
18 Years
38 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Onze Lieve Vrouw Hospital
OTHER
AZ Jan Palfijn Gent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Decleer Wim
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wim Decleer, MD
Role: PRINCIPAL_INVESTIGATOR
FERTILITY CENTER AZ JAN PALFIJN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZ Jan Palfijn
Ghent, Oost-Vlaanderen, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-005676-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.